Skip to main content
Sign In

Anschutz Medical Campus

University of Colorado Denver


The CU Anschutz Medical Campus is a nationally recognized leader in the creation of new knowledge and innovative approaches to improving human health. With research awards and gifts totaling more than $450 million annually, CU Anschutz researchers collaborate with partner and affiliate hospitals, clinics and centers to bring research from the bench to the patient’s bedside.


The CU Anschutz tradition of innovation has created several groundbreaking achievements, including the first liver transplant in the world, the first vaccine for shingles, and the first to use human cell cloning to study genetics and cancer.


Discoveries on the Anschutz Medical Campus have led to new medical devices, pharmaceuticals, diagnostic methods, treatment of debilitating conditions and improved quality of life for patients and consumers worldwide. Since 2002, CU Anschutz technology has led to the filing of 2,000 patent applications and the formation of 60 new companies, funded by more than $914 million in venture capital and public and private equity investment and grants. ​​​​​​​​​​​​​​

Research Resources

Visit Connection Points to search our researcher database and learn about our areas of expertise. Get information about our labs, facilities and clinical trials. Read about our Good Manufacturing Practice facility for cell bio-manufacturing.

Learn more

New weight-loss trial starts for Elipse Balloon

Elipse Ballon
Enrollment for ENLIGHTEN, a U.S. clinical trial for the Elipse® Balloon – the world’s first and only procedureless™ gastric balloon for weight loss, has started at the CU Anschutz Medical Campus. The study is designed to evaluate the safety and efficacy of the Elipse Balloon in 400 individuals. Dr. Shelby Sullivan, associate visiting professor of gastroenterology at the CU School of Medicine and a specialist in endoscopic bariatric weight-loss procedures is leading the trial in Colorado.

Read more